Zalcitabine. Clinical pharmacokinetics and efficacy. (Q40447103)

20 September 2017

1 reference

title

Zalcitabine. Clinical pharmacokinetics and efficacy. (English)

1 reference

20 September 2017

1 reference

D Devineni

1

1 reference

20 September 2017

J M Gallo

series ordinal

2

1 reference

20 September 2017

publication date

1 May 1995

1 reference

Clinical Pharmacokinetics

20 September 2017

published in

1 reference

20 September 2017

volume

28

1 reference

20 September 2017

issue

5

1 reference

20 September 2017

page(s)

351-360

1 reference

Restricted transport of 3'-azido-3'-deoxythymidine and dideoxynucleosides through the blood-brain barrier

20 September 2017

cites work

1 reference

12 December 2020

Preliminary pharmacokinetics of 2',3'-dideoxycytidine in neonatal goats

1 reference

12 December 2020

The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species

1 reference

12 December 2020

Isolation of Lymphocytopathic Retroviruses from San Francisco Patients with AIDS

1 reference

12 December 2020

Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.

1 reference

12 December 2020

Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study

1 reference

12 December 2020

In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors

1 reference

12 December 2020

Pharmacokinetic evaluation of drug interactions with anti-human immunodeficiency virus drugs. V. Effect of soluble CD4 on 2',3'-dideoxycytidine kinetics in monkeys

1 reference

12 December 2020

Pharmacokinetics of 2',3'-dideoxycytidine in rats: application to interspecies scale-up

1 reference

12 December 2020

Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS

1 reference

12 December 2020

Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides

1 reference

12 December 2020

Genetic analysis of 2',3'-dideoxycytidine incorporation into cultured human T lymphoblasts

1 reference

12 December 2020

Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity

1 reference

12 December 2020

Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex.

1 reference

12 December 2020

Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro

1 reference

12 December 2020

Nucleosides. IX. The Formation of 2',3'-Unsaturated Pyrimidine Nucleosides via a Novel β-Elimination Reaction1,2

1 reference

12 December 2020

Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro

1 reference

12 December 2020

Severe Acquired Immunodeficiency in Male Homosexuals, Manifested by Chronic Perianal Ulcerative Herpes Simplex Lesions

1 reference

12 December 2020

Pharmacokinetics of anti-HIV nucleosides in microswine

1 reference

12 December 2020

Disseminated Kaposi's sarcoma in homosexual men.

1 reference

12 December 2020

Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides

1 reference

12 December 2020

Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy

1 reference

12 December 2020

Human immunodeficiency virus inhibition is prolonged by 3'-azido-3'-deoxythymidine alternating with 2',3'-dideoxycytidine compared with 3'-azido-3'-deoxythymidine alone

1 reference

12 December 2020

Dideoxycytidine permeation and salvage by mouse leukemia cells and human erythrocytes

1 reference

12 December 2020

The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys

1 reference

12 December 2020

Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection

1 reference

12 December 2020

Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency

1 reference

12 December 2020

Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

1 reference

12 December 2020

Determination of 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine and 2',3'-dideoxycytidine in biological samples

1 reference

12 December 2020

The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

1 reference

12 December 2020

Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro

1 reference

12 December 2020

Pharmacodynamics of 2′,3′-dideoxycytidine: An inhibitor of human immunodeficiency virus

1 reference

12 December 2020

Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report

1 reference

12 December 2020

Mitochondrial DNA replication does not involve DNA polymerase alpha

1 reference

12 December 2020

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

1 reference

12 December 2020

Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine

1 reference

12 December 2020

Cellular metabolism of 2',3'-dideoxycytidine, a compound active against human immunodeficiency virus in vitro

1 reference

12 December 2020

A human T-lymphotropic retrovirus (HTLV-III) as the cause of the acquired immunodeficiency syndrome

1 reference

12 December 2020

A pilot study of the bioavailability and pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS or AIDS-related complex

1 reference

12 December 2020

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

1 reference

12 December 2020

Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity.

1 reference

12 December 2020

1 reference

12 December 2020

Strategies for antiviral therapy in AIDS.

1 reference

12 December 2020

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro

1 reference

12 December 2020

In vitro toxicity and metabolism of 2',3'-dideoxycytidine, an inhibitor of human immunodeficiency virus infectivity

1 reference

12 December 2020

Synergistic interaction of 2',3'-dideoxycytidine and recombinant interferon-alpha-A on replication of human immunodeficiency virus type 1.

1 reference

12 December 2020

Zidovudine intolerance.

1 reference

12 December 2020

An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction

1 reference

12 December 2020

Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study

1 reference

12 December 2020

10.2165/00003088-199528050-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

20 September 2017

1044500511

0 references

1 reference